Insights from ASH 2025, including anticipated presentations, key takeaways, and how emerging research in paroxysmal nocturnal ...

Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...

Pregnancy exacerbates PNH-related manifestations. Complement inhibition has improved both maternal and fetal outcomes. Most hematologists agree that the benefits of complement inhibition during ...

Artificial intelligence to speed diagnosis, switching complement therapies, ravulizumab during pregnancy, and iptacopan ...

Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta ® (iptacopan) in adult ...

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is ...

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...

Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...

Apellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder known as ...

Novartis AG (NYSE:NVS) on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with ...

Please provide your email address to receive an email when new articles are posted on . Paroxysmal nocturnal hemoglobinuria is a rare hematopoietic disorder characterized by intravascular hemolysis, ...